7 completed, 5 recruiting, 4 active not recruiting, 4 unknown. 12 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 5, Unknown 3, Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Terminated 2, Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Multi-centric Castleman's Disease: new trials by email Literature Review of Multi-centric Castleman's Disease trials Research Report on Multi-centric Castleman's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection, Placebo - Anti IL-6R, Castleman's Disease, Multicentric | Phase 3 | Recruiting | Beijing VDJBio Co., LTD. | 45 | 2025-01-27 | 2026-10-13 |
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease Daratumumab SC - Lymphoma, Primary Effusion | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2024-07-10 | 2026-10-16 |
| Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS) Research questions - Idiopathic Multicentric Castleman's Disease | Unknown | RECORDATI GROUP | 100 | 2023-10-01 | 2023-08-22 | |
| Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers Biospecimen Collection - Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm | Recruiting | AIDS Malignancy Consortium | 200 | 2023-05-10 | 2026-06-01 | |
| Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi Rituximab, Etoposide - Multicentric Castleman Disease | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 15 | 2021-06-22 | 2026-07-30 |
| Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease Siltuximab - Idiopathic Multicentric Castleman's Disease | Phase 2 | Terminated | RECORDATI GROUP | 22 | 2021-03-31 | 2021-04-19 |
| Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease | Active not recruiting | National Cancer Institute (NCI) | 40 | 2021-02-04 | 2026-08-25 | |
| Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial Zanubrutinib - Idiopathic Multicentric Castleman's Disease | Phase 2 | Unknown | Peking Union Medical College Hospital | 30 | 2021-01-01 | 2021-02-09 |
| Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda Rituximab and Hyaluronidase Human, Cyclophosphamide, Vincristine - Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 18 | 2019-10-24 | 2024-01-03 |
| Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease Sirolimus - Castleman Disease, Castleman's Disease, Multicentric | Phase 2 | Active not recruiting | University of Pennsylvania | 7 | 2019-09-25 | 2026-08-20 |
| BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) Bortezomib, Cyclophosphamide, Dexamethason - Idiopathic Multicentric Castleman's Disease | Phase 2 | Unknown | Peking Union Medical College Hospital | 30 | 2019-01-01 | 2019-06-12 |
| TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Thalidomide, cyclophosphamide and prednisone - Multicentric Castleman Disease | Phase 2 | Unknown | Peking Union Medical College Hospital | 25 | 2017-01-01 | 2020-04-16 |
| International Registry for Patients With Castleman Disease Castleman Disease, Castleman's Disease | Recruiting | University of Pennsylvania | 1000 | 2016-10-01 | 2026-03-03 | |
| Castleman Disease Collaborative Network Biobank Sample Collection - Castleman Disease, Castleman's Disease | Withdrawn | Castleman Disease Collaborative Network | 2016-06-01 | 2018-07-31 | ||
| Unlock the Cell: Castleman's Disease Flow Cytometry Study Blood draw/buccal swab - Castleman Disease, Angiofollicular Lymphoid Hyperplasia | Completed | University of Pennsylvania | 130 | 2016-02-01 | 2020-03-26 | |
| Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma liposomal doxorubicin, pomalidomide - Kaposi Sarcoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2016-01-13 | 2026-08-28 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| Tocilizumab for KSHV-Associated Multicentric Castleman Disease Zidovudine, Tocilizumab, Valganciclovir (VGC) - Castleman Disease, Multicentric Castleman Disease | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-09-13 | 2020-10-27 |
| A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Siltuximab - Multicentric Castleman's Disease | Phase 2 | Completed | Janssen Research & Development, LLC | 60 | 2011-04-01 | 2018-05-22 |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Siltuximab, Placebo, Best Supportive Care (BSC) - Multicentric Castleman's Disease | Phase 2 | Completed | Janssen Research & Development, LLC | 79 | 2010-03-18 | 2018-03-21 |
Showing 20 of 24. Sign in to see all of them.
Macular dystrophy, corneal type 1 (7) · Sarcoma, Kaposi (6) · Castleman Disease (5) · Acquired Immunodeficiency Syndrome (4) · HIV Infections (4) · Lymphoma (4) · Burkitt Lymphoma (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, Primary Effusion (3) · Neoplasms (3) · Hyperplasia (2) · Leukemia, Hairy Cell (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2)
Immune System Diseases (15) · Hemic and Lymphatic Diseases (14) · Immunoproliferative Disorders (14) · Lymphatic Diseases (14) · Lymphoproliferative Disorders (13) · Infections (11) · DNA Virus Infections (10) · Neoplasms by Histologic Type (10) · Virus Diseases (10) · Herpesviridae Infections (9) · Neoplasms (9) · Blood-Borne Infections (8) · Communicable Diseases (8) · Genital Diseases (8) · Immunologic Deficiency Syndromes (8)
Cyclophosphamide (4) · Etoposide (3) · Prednisone (3) · Rituximab (3) · siltuximab (3) · Bortezomib (2) · Doxorubicin (2) · Sirolimus (2) · Valganciclovir (2) · Vincristine (2) · Zidovudine (2) · liposomal doxorubicin (2) · CT-P10 (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1)
National Cancer Institute (NCI) (7) · Peking Union Medical College Hospital (3) · University of Pennsylvania (3) · AIDS Malignancy Consortium (2) · Janssen Research & Development, LLC (2) · RECORDATI GROUP (2) · Beijing VDJBio Co., LTD. (1) · Castleman Disease Collaborative Network (1) · Fred Hutchinson Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (17) · China (6) · Belgium (2) · Brazil (2) · Canada (2) · Egypt (2) · France (2) · Germany (2) · Hong Kong (2) · Israel (2) · New Zealand (2) · Norway (2) · Singapore (2) · South Korea (2) · Spain (2)
Robert Yarchoan, M.D. (4) · Joshua Brandstadter, MD, PhD, MSc (2) · Ramya M Ramaswami, M.D. (2) · Anju Keetharuth, PhD (1) · Antonio T. Fojo, MD, PhD (1) · Chris Keuker, MD (1) · David C Fajgenbaum, MD, MBA, MSc (1) · J. Michael Berry, MD (1) · Jeff Bethony (1) · Manoj Menon, MD (1) · Philip Powell, PhD (1) · Vera Krymskaya, PhD, MBA (1) · Yuri Fedoriw, MD (1) · Yvette Kasamon (1)
PMID 31408438, PMID 32206779, PMID 33284946, PMID 38941593, PMID 41845569, PMID 21487108, PMID 24174627, PMID 25042199, PMID 25331113, PMID 28087540, PMID 29675946, PMID 30181172, PMID 30760451, PMID 32106302, PMID 32276276, PMID 32376796, PMID 33377129, PMID 33709329, PMID 33720337, PMID 34265103, PMID 34438448, PMID 35104370, PMID 35488725, PMID 35507638, PMID 35793409, PMID 36433996, PMID 36928290, PMID 37635628, PMID 37656441, PMID 37740179, PMID 37867418, PMID 38168727, PMID 38546960, PMID 39044861, PMID 40184567, PMID 42580681
U01CA121947 (2), 2009 (1), K01TW011470 (1), UM1CA121947 (1)